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Masking, And Susceptibility Of Trials To Selection Bias 
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                             & University of Maryland-              
       Baltimore County 
 
 
It is widely believed that baseline imbalances in randomized clinical trials must necessarily be random. Yet 
even among masked randomized trials conducted with allocation concealment, there are mechanisms by 
which patients with specific covariates may be selected for inclusion into a particular treatment group. This 
selection bias would force imbalance in those covariates, measured or unmeasured, that are used for the 
patient selection. Unfortunately, few trials provide adequate information to determine even if there was 
allocation concealment, how the randomization was conducted, and how successful the masking may have 
been, let alone if selection bias was adequately controlled. In this article we reinforce the message that 
allocation details should be presented in full. We also facilitate such reporting by identifying and clarifying 
the role of specific reportable design features. Because the designs that eliminate all selection bias are rarely 
feasible in practice, our development has important implications for not only the implementation, but also the 
reporting and interpretation, of randomized clinical trials. 
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Introduction 
 
When lecturing on selection bias, we have 
addressed audience questions about how selection 
bias can occur in randomized clinical trials 
(RCTs). After all, it may be argued, if any 
subversion occurred, then the trial was not truly 
randomized. This statement implies that 
randomization confers absolute protection against 
any subversion, so that any covariate imbalances 
must be random. Similar abilities are often 
ascribed to allocation concealment or masking.  
Yet the effect of an action may differ from its 
objective; washed dishes, e.g., may remain dirty; 
cooked food may remain cold; and treated patients 
may remain sick. 
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It is in this light that we critically evaluate 
the ability of masking, allocation concealment, and 
randomization as actually implemented to produce 
treatment groups that differ only randomly. If they 
cannot do so, then observed covariate imbalances 
may be systematic, and may reflect selection bias. 
Observed treatment effects could then be 
attributable to biases, and not to the treatments 
themselves. 
Selection bias can compromise the 
credibility of standard between-group 
comparisons, especially when the trial is 
conducted by a sponsor with a vested interest in 
the outcome (Hogel & Gaus, 1999). Yet details 
sufficient to assess the success of randomization, 
allocation concealment, and masking are rarely 
reported (Kyriakidi & Ioannidis, 2002). 
This draws into question the reliability of 
the results of many RCTs that have been otherwise 
well conducted. In fact, if randomization is 
defined so as to eliminate the possibility of any 
subversion, then we question whether there has 
ever been a truly randomized trial. The irony is 
that until sufficient design details are routinely 
reported, it will be impossible to quantify the 
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extent to which selection bias actually occurs in 
RCTs, yet this lack of reporting is likely due to 
failure to appreciate the extent to which selection 
bias occurs in RCTs. Our development clarifies 
those details that should be presented in RCT 
reports. It is our hope that more RCT reports will 
provide these details, and test for selection bias 
explicitly (Berger & Exner, 1999). 
 
What Are Randomization, Allocation 
Concealment, and Masking? 
In a discussion of the distinction between 
a claim of masking and true masking, Oxtoby et 
al. (1989) pointed out that “the presumption that a 
plan to which one has aspired has come to fruition 
by virtue of aspiration alone is not science, and is 
particularly inapposite for a profession which 
should have a reputation for making clear 
distinctions between fantasy and reality”. This 
profound remark highlights the distinction 
between an action and its effect. Masking may be 
defined as either the process (researchers not 
revealing treatment codes until the database is 
locked) or the result (complete ignorance of all 
trial participants as to which patients received 
which treatments). A masking claim indicates only 
the former; this may help to ensure the ignorance 
of some parties, but is unlikely to ensure the 
desired state of complete ignorance. 
As the legal term “inevitable discovery” 
suggests, knowledge transfers by various 
mechanisms. It may be possible to fool all of the 
people some of the time, or some of the people all 
of the time, but it is not possible to fool all of the 
people all of the time. Just as a speed limit is a 
statement not about how fast drivers drive but 
rather about how fast they are encouraged to 
drive, so too is a policy of masking a statement not 
about who knew what (and when) but rather about 
a process. 
Masking is often said to be possible only 
some of the time, while allocation concealment 
(Schulz, 1995a,b; 1996), which is essentially the 
masking of each allocation just until it is executed, 
is always possible. This confusion of the two 
definitions is a double-standard. If masking is 
possible only some of the time, then clearly 
reference is being made to the result, and not the 
process. 
To be fair, then, one would have to ask if 
the result of allocation concealment is always 
possible. Sealed envelopes have been held to 
lights, phantom patients have been enrolled, and 
locked files have been raided to determine 
upcoming treatment allocations in successful 
subversions of allocation concealment (Schulz, 
1995a). Also, it may be clear what a given patient 
would receive, if enrolled, if cluster randomization 
(Jordhoy et al., 2002) or minimization (Pocock & 
Simon, 1975) is used. Drug bottle numbers can 
also lead to prediction (Kuznetsova, 2002). So 
only the process of allocation concealment, but not 
its result, can be ensured. Without the result of 
allocation concealment, selection bias remains a 
concern. 
 
Mechanisms for Selection Bias, and Specific 
Countermeasures 
To focus ideas, we confine our attention to 
selection bias that interferes with internal validity 
(a fair comparison, Mark, 1997); we do not 
consider external validity. Groups of patients to be 
compared may differ in important ways even 
before any intervention is applied (Prorok, 
Hankes, & Bundy, 1981). These baseline 
imbalances cannot be attributed to the 
interventions, but they can interfere with and 
overwhelm the comparison of the interventions 
(Green & Byar, 1984). 
If treatments are independent of patient 
characteristics, then any baseline imbalances (even 
if statistically significant) are due to chance 
variation only. This is one reason often cited for 
using randomization. 
On the other hand, a systematic 
explanation for the imbalances, known or 
unknown, would constitute selection bias, even if 
the imbalances are not statistically significant, or 
even readily observed (Berger & Exner, 1999). 
We present a sequence of mechanisms by which 
selection bias may occur, starting with 
observational studies in Section A, and such 
countermeasures as randomization, allocation 
concealment, and masking (see Table 1). 
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Table 1: What to Report in Randomized Clinical Trials To Control Selection Bias 
_____________________________________________________________________________________ 
 
Concern Report 
Differential Allocation Discretion Planned allocation proportions 
Number of screened and randomized patients by the group to which 
they were or would have been randomized had they been randomized 
 
Deferred Enrollment List patients who were screened twice or more, or that there were 
none 
 
Allocation Concealment Specific means of concealing the future allocations 
 
Predicted Allocations  Specific restrictions on the randomization (including block sizes) 
 Specific methods of concealing the past allocations (masking) 
 Evidence of unmasking (including differential rates of observable 
adverse events, any emergencies requiring intentional unmasking, 
and rates of correct treatment group guesses at de-briefing) 
 
Baseline Imbalances Compare baseline covariates across treatment groups 
 
Selection Bias Graph key covariates against P{active}, as in Berger and Exner 
(1999) 
 Graph response against P{active} within each treatment group, per 
Berger and Exner (1999). 
 List stratification errors (if any), or that there were none 
_____________________________________________________________________________________ 
 
A. Selection Bias in Observational Studies or with 
Consumer Randomization 
Investigators may assign treatments based 
on patient characteristics (Green & Byar, 1984; 
Rubin, 1977). Patients may select either their 
treatment or, with consumer randomization (Bird, 
2001), their randomization probability, at least 
from among a given set of choices. Allocation 
discretion may be available to the patient, the 
investigator, both, or neither (dictated allocation). 
Those patients selecting one treatment or 
probability may differ systematically from those 
selecting another (Green & Byar, 1984), so 
dictated allocation (no freedom of choice) is a 
countermeasure to prevent patient characteristics 
from influencing the allocation sequence through 
either overt treatment assignment based on patient 
characteristics or self-selection. 
 
B. Selection Bias with Dictated Allocation 
If allocation is alternated, then either 
patients with even accession numbers or patients 
with odd accession numbers receive the active 
treatment. The others receive the control. This 
dictated allocation would prevent the type of 
selection bias considered in Section A. But with 
sequential accrual, knowledge of the upcoming 
treatment, and enrollment discretion (Chalmers, 
1990), an investigator could deny enrollment to 
patients lacking the characteristics that would 
make them “suitable” to receive the upcoming 
treatment (Schulz, 1995a; Schulz & Grimes, 
2002a). 
The selection bias enabled by the 
predictable allocation sequence (Schulz & Grimes, 
2002b) can be controlled by creating instead an 
unpredictable allocation sequence, or randomizing 
(Rosenberger & Lachin, 2002). The second 
countermeasure is the use of actual (not virtual, 
quasi-, or pseudo-) randomization (Berger & 
Bears, 2003) to prepare the allocation sequence. 
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C. Selection Bias with Dictated Allocation and 
Randomization 
Urn randomization (Wei & Lachin, 1988) 
is conducted by tossing a (possibly biased) coin 
each time a patient is to be allocated. Heads 
indicates active treatment, and tails indicates 
control. There is no actual allocation discretion, 
yet having screened and evaluated a given patient, 
the investigator might exercise de facto  allocation 
discretion to reject the toss and repeat until the 
preferred allocation is observed. 
Another mechanism for selection bias 
with dictated allocation and randomization would 
be possible if minimization, or dynamic 
randomization (Pocock & Simon, 1975), were 
used to force balance with respect to certain 
covaria tes. The allocation is determined by 
minimizing an imbalance function, and 
randomization may be used to break the ties. So 
there is both dictated allocation and 
randomization. Yet because most allocations will 
be deterministic, it would be possible to determine 
the allocation to be made once a patient has been 
identified. A patient enrollment decision may be 
based on a combination of the treatment to be 
assigned and values of observed covariates that 
were not used to define the imbalance function.  
Randomization is conventional if the allocation 
sequence is generated in advance of screening any 
patients, and unconventional otherwise. 
Conventional randomization prevents the types of 
selection bias discussed in this section, and is our 
third countermeasure. 
 
D. Selection Bias with Dictated Allocation and 
Conventional Randomization 
As in Section B, selection bias may result 
from enrollment discretion and advance 
knowledge of the allocation sequence; the latter 
may be facilitated by conventional randomization, 
as the allocation sequence may be posted publicly 
before patients are screened (Schulz & Grimes, 
2002a). A countermeasure to eliminate this 
advance knowledge is that each allocation be 
determined only after the patient to be enrolled is 
identified (Clarke, 2002), as occurs with 
minimization (Pocock & Simon, 1975). Either the 
allocation to be made or the patient to be enrolled 
has to be selected first; whichever it is may 
influence the other, and the biases possible with 
unconventional randomization (Section C) are at 
least as serious as the biases possible with 
conventional randomization. 
Unconventional randomization may not be 
able to eliminate advance knowledge of patient 
characteristics, but one might hope to eliminate 
advance knowledge of the allocation sequence 
with conventional randomization and the fourth 
countermeasure, allocation concealment, which is 
often taken to mean precisely this lack of advance 
knowledge. But recall that allocation concealment 
signifies only that the allocation codes are not 
intentionally revealed. Even with steps to ensure 
that these codes cannot be observed, e.g. by 
holding an envelope to a light (Schulz, 1995a,b), it 
is not possible to enumerate, and rule out, all 
mechanisms by which allocations can be observed. 
We are not prepared to take the success of 
allocation concealment on faith in an actual trial; 
we do so for the purpose of this article to 
demonstrate that even in this unrealistically 
optimistic case, subversion is still possible. 
 
E. Selection Bias with (D) and Allocation 
Concealment 
In a randomized depression study of nurse 
telehealth care (Hunkeler et al., 2000), the initial 
40:60 randomization to two groups later became 
40:20 to those same two groups, with the 
remaining 40% allocated to a new third group. If 
the change in allocation proportions was planned 
(which need not be the case; see Lippman et al., 
2001), then even with allocation concealment it 
may still be possible to predict (but not observe) 
future allocations. Knowing that more late patients 
than early patients would be allocated to the third 
group constitutes advance knowledge of the 
allocations which, though imperfect, allows for 
deferred enrollment (Schulz, 1996) of those 
subjects most “suitable” for the third group until 
after the new proportions took effect. The fifth 
countermeasure, then, is the fixed allocation 
proportions that prevent this. 
 
F. Selection Bias with (E) and Fixed Allocation 
Proportions 
Randomization is unrestricted (Schulz & 
Grimes, 2002b) if a patient’s likelihood of 
receiving either treatment is independent of all 
previous allocations, and is restricted (ter Riet & 
Kessels, 1995) otherwise. The random allocation 
rule (Schulz & Grimes, 2002b), in which both 
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treatment groups must be assigned equally often, 
is one form of restricted randomization, as the 
final allocation would be determined by the prior 
ones. Even with allocation concealment and fixed 
allocation proportions, patterns created by 
restrictions on the randomization allow prediction 
of the allocation sequence. Berger and Exner 
(1999) quantified this extent of advance 
knowledge with the probability, P{active}, of a 
given patient being allocated to the active group 
given the previous allocations. 
With 1:1 allocation, P{active}=0.5 for the 
first patient; with alternation (Section B), 
P{active} is always either 0 or 1. Note that 
P{active} reflects the restrictions on the allocation 
sequences, and becomes a patient characteristic 
only after that patient is randomized. With 
enrollment discretion, P{active} may be used, in 
conjunction with the estimated potential outcomes 
of each patient to each treatment, say 
Y={Y(A),Y(C)} for the active and control 
treatments, respectively, as a basis for enrollment 
decisions. 
Gender, age, race, pre-existing medical 
conditions, or other baseline characteristics may 
be considered in deriving the value of Y for a 
given patient. Based on Y, the investigator might 
select a range of P{active} values for which the 
patient would be enrolled. If the P{active} value at 
the time this patient is screened happens to fall 
outside of this patient’s P{active} range, then the 
patient will be denied enrollment, and another 
patient will be screened. Only when a patient is 
found with a P{active} range to match the actual 
P{active} value will the patient be enrolled. 
Selection bias occurs if the P{active} 
range is restricted based on Y. It would be 
possible, e.g., to enroll patients only if P{active} 
and Y are both large (suppose that larger Y values 
indicate better responses) or both small, but not if 
they are discordant (Schulz, 1995a). This 
possibility is depicted in Table 2, using 
randomized blocks of size four to calculate 
P{active} (Berger & Exner, 1999). Notice that not 
only does treatment assignment for randomized 
patients depend upon the allocation sequence, but 
in fact Patients #S5, #S7, #S9, and #S10 may or 
may not be randomized depending on the 
allocation sequence, and Patient #S3 cannot get 
the control. 
 
Discussion 
 
Few RCT reports make any effort to address the 
potential for selection bias. Presumably, this is due 
to unrealistically optimistic definitions of 
randomization, allocation concealment, and 
masking. Unfortunately, even in combination, 
these design features as implemented cannot 
eliminate selection bias. One may argue that while 
selection bias is possible  in theory, its mechanisms 
are implausible, especially when the main analyses 
have low p-values. 
 Unfortunately, history has demonstrated 
the fallibility of the plausibility test; at best low p-
values rule out (probabilistically) chance events, 
but they do not rule out biases (Berger, 2000; 
Berger et al., 2000; Grimes and Schulz, 2002). 
Because of the one-sponsor problem (Hogel & 
Gaus, 1999) and the vested interest the one 
sponsor usually has in the outcome of the trial, the 
best way to offer a convincing argument that a 
trial was free of a certain bias is to eliminate the 
possibility of its occurrence. Hence, the burden 
needs to be on the researchers to demonstrate the 
reliability of their results. In this article we have 
presented a number of countermeasures, few 
combinations of which would eliminate the 
potential for selection bias. In most cases, then, it 
is unrealistically optimistic to believe that RCTs 
are insulated from severe bias (Schulz, 1996). 
 We are hopeful that the information 
presented in Table 1 will accompany reports of 
future trials, preferably in the text of the article, 
but possibly in an accompanying web site. Such 
transparency would enable readers to determine 
the extent to which various mechanisms for 
selection bias were possible in a given trial, and 
the extent to which it appears as though there 
actually was selection bias. The refined measures 
of trial quality could be used in determining the 
extent to which specific trials influence policy and 
meta-analyses. This would exert pressure on those 
who design trials to design better trials. We are 
hopeful that journal editors, regulators, and 
granting institutions will rely, in part, on this 
information to make their important decisions. 
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  Table 2: Selection Bias with Randomization and Allocation Concealment. 
 
     {(A C C A); (C C A A)}  {(A C A C); (C A A C)} 
 S P{active} Range* P{active} Randomized P{active} Randomized  
 S1 [0.50,1.00] 0.50 Active 0.50 Active  
 S2 [0.00,0.33] 0.33 Control 0.33 Control  
 S3 [1.00,1.00] 0.50 - 0.50 -  
 S4 [0.00,0.50] 0.50 Control 0.50 Active  
 S5 [0.50,1.00] 1.00 Active 0.00 -  
 S6 [0.00,0.50] 0.50 Control 0.00 Control  
 S7 [0.00,0.50] 0.67 - 0.50 Control  
 S8 [0.67,1.00] 0.67 Control 0.67 Active  
 S9 [0.67,1.00] 1.00 Active 0.50 -  
 S10 [0.00,0.50] 1.00 - 0.50 Active  
 S11 [0.33.0.67] 1.00 - 0.00 -  
 S12 [0.00,1.00] 1.00 Active 0.00 Control  
 
 
*The range of P{active} values for which the patient gets randomized. P{active} 
computed according to the formula of Berger and Exner [3] using the randomized 
block procedure with a fixed block size of four. Not only does treatment assignment 
for randomized patients depend upon the allocation sequence, but in fact Patients 
#S5, #S7, #S9, and #S10 may or may not be randomized depending on the 
allocation sequence, and Patient #S3 cannot get the control. 
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